Ultragenyx Pharmaceutical (RARE) Depreciation & Amortization (CF) (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $8.0 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 11.11% year-over-year to $8.0 million in Q1 2026; TTM through Mar 2026 was $34.0 million, a 5.96% decrease from a year earlier, with the FY2025 full-year figure at $35.0 million, down 2.78% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $8.0 million, down from $8.8 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for RARE reached as high as $9.5 million in Q4 2024 and fell as low as $4.1 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $7.2 million across 5 years, with a median of $8.2 million in 2023.
• Across the five-year window, Depreciation & Amortization (CF) surged 68.93% in 2024 and fell 11.11% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $5.0 million in 2022, then jumped by 65.66% to $8.2 million in 2023, then advanced by 16.12% to $9.5 million in 2024, then retreated by 7.88% to $8.8 million in 2025, then slipped by 8.94% to $8.0 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $8.0 million in Q1 2026, $8.8 million in Q4 2025, and $8.6 million in Q3 2025.